Chewable Tablet Adverse Events, Manufacturing Slips Prompt FDA Guidance
This article was originally published in The Pink Sheet Daily
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
You may also be interested in...
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.
Moeller, CFO since 2009, will retain vice chairman and COO posts and continue heading P&G’s enterprise markets, the firm’s smaller markets,